I agree that this site is using cookies. You can find further informations here.
X
Iwasaku, Masahiro
127  results:
Search for persons X
?
1

Initial AXL and MCL‐1 inhibition contributes to abolishing ..:

Matsui, Yohei ; Yamada, Tadaaki ; Katayama, Yuki...
Cancer Science.  , 2024
Link: https://doi.org/10.1111/..
 
?
2

Efficacy and Safety of Docetaxel plus Ramucirumab for Patie..:

Onoi, Keisuke ; Yamada, Tadaaki ; Morimoto, Kenji...
Targeted Oncology.  19 (2024)  3 - p. 411-421 , 2024
Link: https://doi.org/10.1007/..
 
?
3

Prognostic impact of clinical factors for immune checkpoint..:

Takei, Shota ; Kawachi, Hayato ; Yamada, Tadaaki...
Frontiers in Immunology.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
4

Nationwide data from comprehensive genomic profiling assays..:

Ishida, Masaki ; Iwasaku, Masahiro ; Doi, Toshifumi...
Cancer Science.  115 (2024)  5 - p. 1656-1664 , 2024
Link: https://doi.org/10.1111/..
 
?
5

Prospective Observational Study of Ramucirumab Plus Docetax..:

Katayama, Yuki ; Yamada, Tadaaki ; Sawada, Ryo...
The Oncologist.  29 (2024)  5 - p. e681-e689 , 2024
Link: https://doi.org/10.1093/..
 
?
6

Unraveling the influence of TTF-1 expression on immunothera..:

Nishioka, Naoya ; Kawachi, Hayato ; Yamada, Tadaaki...
Frontiers in Immunology.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
7

Comparing Three Different Anti–Programmed Death-Ligand 1 An..:

Katayama, Yuki ; Yamada, Tadaaki ; Morimoto, Kenji...
JTO Clinical and Research Reports.  5 (2024)  3 - p. 100644 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Clinical Efficacy and Safety of First- or Second-Generation..:

Morimoto, Kenji ; Yamada, Tadaaki ; Takeda, Takayuki...
Targeted Oncology.  18 (2023)  5 - p. 657-665 , 2023
Link: https://doi.org/10.1007/..
 
?
9

Adaptive resistance to lorlatinib via EGFR signaling in ALK..:

Katayama, Yuki ; Yamada, Tadaaki ; Tanimura, Keiko...
npj Precision Oncology.  7 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
10

Predictive value of p53 and AXL immunostaining for the effi..:

Morimoto, Kenji ; Yamada, Tadaaki ; Sawada, Ryo...
Cancer Immunology, Immunotherapy.  72 (2023)  6 - p. 1699-1707 , 2023
Link: https://doi.org/10.1007/..
 
?
11

Endobronchial metastasis of hepatocellular carcinoma treate..:

Takei, Shota ; Yoshimura, Akihiro ; Yamamoto, Chie...
Respirology Case Reports.  11 (2023)  9 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
12

Significance of localized expression of full-length growth ..:

Morita-Tanaka, Satomi ; Miyagawa-Hayashino, Aya ; Yamada, Tadaaki...
Supportive Care in Cancer.  31 (2023)  5 - p. , 2023
Link: https://doi.org/10.1007/..
 
?
13

Prospective Observational Study Evaluating the Prognostic V..:

Morimoto, Kenji ; Yamada, Tadaaki ; Takeda, Takayuki...
Drugs & Aging.  40 (2023)  6 - p. 563-571 , 2023
Link: https://doi.org/10.1007/..
 
?
14

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Tre..:

Morimoto, Kenji ; Yamada, Tadaaki ; Kawachi, Hayato...
Targeted Oncology.  18 (2023)  6 - p. 915-925 , 2023
Link: https://doi.org/10.1007/..
 
?
15

Rationale and design of phase II clinical trial of dual inh..:

Kawachi, Hayato ; Yamada, Tadaaki ; Yoshimura, Akihiro...
Therapeutic Advances in Medical Oncology.  15 (2023)  - p. , 2023
Link: https://doi.org/10.1177/..
 
1-15